Patrick Roberts, Chief Executive Officer at Incyclix Bio, most recently served as the head of translational medicine at G1 Therapeutics. His scientific, operational and leadership contributions helped G1 grow from an incubated start-up to a publicly traded company with multiple clinical programs. His early scientific contributions laid the foundation for the myelopreservation concept and during his time as project leader, he had the unique opportunity to guide trilaciclib from discovery to patients. With a breadth of drug development experience ranging from proof-of-concept biology to NDA submission, Patrick is well positioned to lead the team at Incyclix Bio.